MedTrace Logo

Prospective, 6 Month, Open Label, Conversion Study From Mycophenolate Mofetil (MMF) to PRMYFORTIC*

NCT00715468 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 59

Last updated 2014-12-12

No results posted yet for this study

Summary

Treatment with MMF often results in adverse GI events, which can lead to dose reductions of MMF and decreased graft function. Enteric-coated mycophenolate sodium (MYFORTIC\*) was developed as an alternative formulation of MPA to improve upper GI tract side effects. An improvement in the severity of GI side effects could result in an increased tolerance to MPA and an improvement in patient quality of life. This study will use the GSRS to evaluate improvement in gastrointestinal symptoms.

Conditions

  • Late Complication From Kidney Transplant

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Maisonneuve-Rosemont Hospital

    lead OTHER

Principal Investigators

  • Suzon Collette, Md · Maisonneuve-Rosemont Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2013-12-31
Completion
2014-04-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00715468 on ClinicalTrials.gov